Zoom: We all thought we'd be trading much higher t
Post# of 30028
I can't reconcile Gerald's statement that "we don't know if we'll even need a RS to up list..." with the fact we are trading at .106 cents, and we didn't land a LymPro JV partner.
Gerald's statement has caused many shareholders to hope that we have catalysts that will pop us above $2 dollars in the next 2 months. I think that is unrealistic. I don't think that lofty hope should be the basis of shareholders voting on massive potential future dilution.
Let's see some of the "financial engineering" to increase shareholder value first, then vote to authorize more potential dilution after.